title: [Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients].
abstract: Cytomegalovirus (CMV) infection remains an important complication of transplantation. The last decade has been characterized by improvements to management that has reduced its morbidity and mortality. The advance has been particularly important in the diagnosis and prevention. Several techniques have been developed that allow the increasingly rapid and sensitive diagnosis. The different preventive strategies include use of appropriate blood products, immune globulin, and antiviral agents either as prophylaxis or pre-emptive therapy. The development of effective oral drugs as valganciclovir also represents a new advance. It is necessary to summarize these advances to facilitate the development of local policies reflecting recent changes. The Group of Study of Infections in Transplantation (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) has therefore produced actual recommendations in the management of CMV infection after transplantation.
authors.affiliation: Unidad de Enfermedades Infecciosas, Hospital Reina Sofía, Córdoba, España. julian.torre.sspa@juntadeandalucia.es
authors.forename: Julián
authors.initials: J
authors.lastname: Torre-Cisneros
authors.forename: Jesús
authors.initials: J
authors.lastname: Fortún
authors.forename: José María
authors.initials: JM
authors.lastname: Aguado
authors.forename: Rafael
authors.initials: R
authors.lastname: de la Cámara
authors.forename: José Miguel
authors.initials: JM
authors.lastname: Cisneros
authors.forename: Joan
authors.initials: J
authors.lastname: Gavaldá
authors.forename: Mercé
authors.initials: M
authors.lastname: Gurguí
authors.forename: Carlos
authors.initials: C
authors.lastname: Lumbreras
authors.forename: Carmen
authors.initials: C
authors.lastname: Martín
authors.forename: Pilar
authors.initials: P
authors.lastname: Martín-Dávila
authors.forename: Miguel
authors.initials: M
authors.lastname: Montejo
authors.forename: Asunción
authors.initials: A
authors.lastname: Moreno
authors.forename: Patricia
authors.initials: P
authors.lastname: Muñoz
authors.forename: Albert
authors.initials: A
authors.lastname: Pahissa
authors.forename: José Luis
authors.initials: JL
authors.lastname: Pérez
authors.forename: Montserrat
authors.initials: M
authors.lastname: Rovira
authors.forename: Angel
authors.initials: A
authors.lastname: Bernardos
authors.forename: Salvador
authors.initials: S
authors.lastname: Gil-Vernet
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Quijano
authors.forename: Gregorio
authors.initials: G
authors.lastname: Rábago
authors.forename: Antoni
authors.initials: A
authors.lastname: Román
authors.forename: Evaristo
authors.initials: E
authors.lastname: Varó
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D009894:Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control* / Q000821:virology; D016377:Organ Transplantation; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents